Company Overview - Nanjing Huangpu Grand Hotel Co., Ltd. was established on September 12, 2002, with a registered capital of RMB 13.848759 million [1] - The company operates in the accommodation and catering industry, providing lodging services, dining services, and other supporting services [1] Financial Reporting Basis - The financial statements are prepared based on the going concern assumption and in accordance with the accounting standards issued by the Ministry of Finance [2] - The accounting records are maintained on an accrual basis, with historical cost as the measurement basis, except for certain financial instruments [2] Important Accounting Policies - The financial statements reflect the company's financial position as of March 31, 2025, December 31, 2024, and December 31, 2023 [2] - The company uses a 12-month operating cycle for classifying assets and liabilities [3] Business Combinations - Business combinations are classified into those under common control and those not under common control [3][4] - For combinations under common control, assets and liabilities are measured at their book values on the merger date [3] - For combinations not under common control, the acquisition cost includes the fair value of assets transferred, liabilities assumed, and equity securities issued [4][5] Consolidated Financial Statements - The scope of consolidation is determined based on control, which includes having the power to govern financial and operating policies [6] - The financial statements of subsidiaries are adjusted to align with the company's accounting policies and periods [7] Financial Instruments - Financial assets are classified based on the business model and cash flow characteristics, including those measured at amortized cost and those measured at fair value [11][12] - The company recognizes impairment losses based on expected credit losses for financial assets [19][20] Inventory and Costing - Inventory includes raw materials and finished goods, valued using the first-in, first-out method [23] - The company assesses the net realizable value of inventory and recognizes impairment when necessary [24] Long-term Equity Investments - Long-term equity investments are accounted for using the equity method for investments where the company has significant influence or joint control [26][27] - The initial investment cost is determined based on the fair value of identifiable net assets at the acquisition date [25][26]

中信建投证券股份有限公司 关于南京商贸旅游股份有限公司 本次方案调整不构成重组方案重大调整的核查意见 "公司"）召开第十届二十五次董事会，审议通过了《关于〈南京商贸旅游股份 有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案〉及其摘 要的议案》等议案，并披露了《南京商旅发行股份及支付现金购买资产并募集配 套资金暨关联交易预案》及相关公告，南京商旅拟通过发行股份及支付现金的方 式购买南京旅游集团有限责任公司（以下简称"旅游集团"）持有的南京黄埔大 酒店有限公司（以下简称"黄埔酒店"）100%股权、南京商厦股份有限公司（以 下简称"南京商厦"）持有的南京南商商业运营管理有限责任公司（以下简称"南 商运营"）49%股权并募集配套资金（以下简称"本次重组"、"本次交易"）。 整公司发行股份及支付现金购买资产并募集配套资金暨关联交易方案且本次方 案调整构成重大调整的议案》 《关于 <南京商贸旅游股份有限公司发行股份及支付> 现金购买资产并募集配套资金暨关联交易报告书（草案）>及其摘要的议案》等 有关议案，对本次重组方案进行了调整，拟不再收购南京商厦持有的南商运营 持有的黄埔酒店 100%股权并募集配套资金。 ...

INDIANAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG) announced today the release of its annual Corporate Responsibility Report, which provides a comprehensive overview of the Company’s strategy and initiatives regarding corporate responsibility practices and policies. The report also details progress, measurements, and case studies around the Company’s goals and related operations. “KRG’s corporate responsibility initiatives reflect our inherent dedication to advancing sustainabilit ...

Financial results FQ3 2025 Safe harbor statement During the course of this meeting, we may make projections or other forward-looking statements regarding market demand and supply, market and pricing trends and drivers, the impact of technologies such as AI, the impact of our reorganization, cost reductions, our manufacturing projects and related investments, expected product volume production, our market position, expected product announcements, capabilities of our future products and technologies, future e ...

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. plans to offer shares of its common stock and warrants in a public offering to fund research and development activities and for general corporate purposes [1][2]. Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [5]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and have been granted composition of matter patents in multiple regions [5]. Offering Details - The offering will be conducted under an effective shelf registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission (SEC) [3]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2].

Financial Performance - Net earnings attributable to common shareholders for Q2 2025 were $88 million, or $0.40 per diluted common share, down from $145.7 million, or $0.64 per diluted common share in Q2 2024[2][10]. - Total net revenues for Q2 2025 were $1.63 billion, a slight decrease from $1.66 billion in Q2 2024, with year-to-date revenues at $3.23 billion compared to $3.39 billion in the previous year[2][10]. - Net earnings attributable to common shareholders for the three months ended May 31, 2025, were $88,017, compared to $145,736 in 2024, a decrease of approximately 39.5%[16]. - Net earnings from continuing operations for the three months ended May 31, 2025, were $91,395,000, a decrease of 40.8% compared to $154,647,000 for the same period in 2024[18]. - The net earnings attributable to common shareholders for basic earnings per share for the six months ended May 31, 2025, was $215,955,000, down from $301,237,000 in the same period of 2024, a decline of 28.4%[18]. Revenue Breakdown - Investment banking net revenues totaled $786 million for Q2 2025, up 6.4% year-over-year, driven by a 61% increase in Advisory revenues[6][10]. - Capital Markets net revenues were $704 million for Q2 2025, slightly down from $707 million in Q2 2024, with Equities net revenues increasing by 24% to $526 million[7][10]. - Asset Management fees and investment return revenues for Q2 2025 were $71 million, a 43% increase from the prior year quarter, attributed to improved performance across several strategies[8][10]. - Total revenues for the three months ended May 31, 2025, were $2,494,315, compared to $2,516,296 for the same period in 2024, reflecting a decrease of approximately 0.9%[16]. - Net revenues for the six months ended May 31, 2025, were $3,227,466, down from $3,394,648 in 2024, representing a decline of about 4.9%[16]. Expenses and Costs - Total non-interest expenses for the three months ended May 31, 2025, were $1,499,546, compared to $1,428,691 in 2024, an increase of approximately 4.9%[16]. - Interest expense for the six months ended May 31, 2025, was $1,739,713, compared to $1,673,590 in 2024, reflecting an increase of about 3.9%[16]. - Compensation and benefits for the three months ended May 31, 2025, were $854,839, compared to $861,993 in 2024, a slight decrease of approximately 0.2%[16]. - Brokerage and clearing fees for the six months ended May 31, 2025, were $239,181, compared to $220,206 in 2024, representing an increase of about 8.6%[16]. Shareholder Metrics - The company declared a quarterly cash dividend of $0.40 per common share, payable on August 29, 2025[3]. - Return on adjusted tangible shareholders' equity from continuing operations was 5.5% for Q2 2025, down from 9.1% in Q2 2024[2][10]. - The book value per common share increased to $49.96 in Q2 2025, up from $46.57 in Q2 2024[2][10]. - The weighted average diluted common shares outstanding for the three months ended May 31, 2025, were 221,897, a decrease from 226,146 in the same period of 2024[18]. - Common shares outstanding as of May 31, 2025, totaled 206,272 thousand, with adjusted fully diluted shares outstanding at 254,564 thousand[22]. Tax and Regulatory - The effective tax rate from continuing operations was 32.3% for Q2 2025, compared to 32.1% for the prior year quarter[10]. - The company reported an income tax expense of $43,506 for the three months ended May 31, 2025, compared to $73,107 in 2024, a decrease of approximately 40.5%[16]. Operational Insights - Management expressed optimism for the second half of 2025, citing a strong backlog and increased client discussions around capital formation and strategic opportunities[4][5]. - The company reported a leverage ratio of 6.5 for the three months ended May 31, 2025, compared to 6.8 for the same period in 2024[17]. - The number of employees at the end of the reporting period was 7,601, a slight increase from 7,577 in the previous year[17]. - Cash and cash equivalents as of May 31, 2025, totaled $1,126,000,000, compared to $1,117,000,000 as of May 31, 2024, reflecting a growth of 0.8%[17]. Discontinued Operations - The company experienced net losses attributable to noncontrolling interests of $7,668,000 for the three months ended May 31, 2025, compared to $3,785,000 in the same period of 2024[18]. - The company experienced a net earnings impact from discontinued operations of $5,861 thousand for the six months ended May 31, 2025[20].

中信证券股份有限公司 关于 中国建设银行股份有限公司 向特定对象发行 A 股股票 之上市保荐书 保荐人（联席主承销商） 住所：广东省深圳市福田区中心三路 8 号 卓越时代广场（二期）北座 二〇二五年六月 中国建设银行股份有限公司 向特定对象发行 A 股股票上市保荐书 声 明 中信证券股份有限公司（以下简称"中信证券""保荐人"或"本保荐人"） 接受中国建设银行股份有限公司（以下简称"建设银行""发行人"或"公司"） 的委托，担任建设银行本次向特定对象发行 A 股股票（以下简称"本次发行"） 的保荐人，为本次发行出具上市保荐书。 保荐人及指定的保荐代表人根据《中华人民共和国公司法》《中华人民共和 国证券法》 《上市公司证券发行注册管理办法》 《证券发行上市保荐业务管理办法》 （以下简称《保荐办法》）等有关法律、法规和中国证券监督管理委员会、上海 证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、 行业执业规范和道德准则出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书所有简称释义，如无特别说明，均与《中国建设银行股份有限 公司向特定对象发行 A 股股票募集说明书》中相同。 中国 ...

Core Viewpoint - Allete's shares have entered oversold territory with a Relative Strength Index (RSI) reading of 29.7, indicating potential buying opportunities as heavy selling may be exhausting [1][2][3] Group 1: Stock Performance - Allete shares traded as low as $63.555, with a current trading price of $63.65, reflecting a decrease of approximately 0.3% on the day [1][3] - The 52-week range for Allete shares is between $61.51 (low) and $66.40 (high) [3] Group 2: Technical Indicators - The average RSI for the energy stocks universe is 51.1, while WTI Crude Oil has an RSI of 47.5, and Henry Hub Natural Gas is at 41.4 [2] - The 3-2-1 Crack Spread RSI is currently at 45.6, indicating a relatively stronger position compared to Allete's RSI [2]

Company Overview - Techcon, part of OK International and Dover, is a leader in precision fluid dispensing technologies, recently launching a new line of Side-by-Side (SBS) Dispensing Cartridges for various industries including electronics, industrial, medical device, and automotive [1][5] - OK International, a global manufacturer of bench tools and equipment, focuses on operational excellence and innovation, with core brands including Metcal and Techcon [6] - Dover Corporation is a diversified global manufacturer with annual revenue exceeding $7 billion, operating across five segments and employing approximately 24,000 people [7] Product Launch - Techcon's SBS Cartridge is designed for precise metering and dispensing of 2-component (2K) adhesives and sealants, available in sizes of 50 ml and 200 ml, with mixing ratios of 1:1, 2:1, and 10:1 [2][3] - The SBS Cartridges are made of polypropylene, ensuring compatibility with a wide range of chemicals, and are designed to work with standard cartridge guns [3] Market Application - The new SBS line is aimed at industries that regularly utilize dual cartridge dispensing for two-part materials, enhancing the ability to package, mix, and dispense 2K materials efficiently [3]

Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (Eu ...